Movano has announced that it will launch its Evie Ring this September in the US. The company has said that progress on its 510(k) submission to the FDA, linked to the wearable’s heart rate and SpO2 (blood oxygen level) tracking features, is progressing well, with final documentation expected to be submitted to the FDA in June.
Movano notes that the September launch would go ahead even if it did not receive FDA approval before this date, starting as a wellness device before transitioning to a medical device. In its Q1 results statement, the company also notes that the second round of beta testing is due to start in July. The Movano Evie Ring was unveiled late last year, a similar device to the Oura Smart Ring. The new health-tracking wearable can monitor heart rate, respiration rate and skin temperature. Recent tests have shown that Evie’s heart rate monitor is highly accurate, with a margin of error of under one beat per minute.
You can also use the ring to monitor your step count and sleep health, with health insights provided in an accompanying app. Plus, the company hopes to add blood pressure and glucose level tracking in the future. The Evie will cost US$269, with no subscription required. This is a marked difference between Movano’s wearable and the Oura Smart Ring, which costs US$299 and requires a monthly subscription of US$5.99 to access all features. It is unclear how the company plans to roll out the wearable to other markets.
Source(s)
Movano, Gadgets & Wearables